Dr. Pagano is the Chief Scientific Officer and interim CEO of LungLifeAI (https://www.lunglifeai.com) which is a lung cancer diagnostics company focused on transforming cancer diagnosis and management through the artificial intelligence-enabled molecular analysis of cancer biomarkers in blood. Dr. Pagano earned his Ph.D. in Molecular Pharmacology from University of California, Los Angeles in 2015. Since then, he has been associated with LungLifeAI, and has held several leadership positions. His research interests are lung cancer biology, especially in clinically actionable precision medicine strategies